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ABSTRACT
Mechanisms of gene repression by transforming
growth factor-beta (TGF-beta) are not well
understood. TGF-beta represses transcription of
pulmonary surfactant protein-B gene in lung
epithelial cells. Repression is mediated by SMAD3
through interactions with NKX2.1 and FOXA1,
two key transcription factors that are positive
regulators of SpB transcription. In this study, we
found that SMAD3 interacts through its MAD
domains, MH1 and MH2 with NKX2.1 and FOXA1
proteins. The sites of interaction on NKX2.1 are
located within the NH2 and COOH domains,
known to be involved in transactivation function.
In comparison, weaker interaction of FOXA1 winged
helix, and the NH2-terminal domains was
documented with SMAD3. Both in vitro studies and
in vivo ChIP assays show that interaction of SMAD3
MH1 and MH2 domains with NKX2.1 and FOXA1
results in reduced binding of NKX2.1 and FOXA1 to
their cognate DNA-binding sites, and diminished
promoter occupancy within the SpB promoter.
Thus, these studies reveal for the first time a
mechanism of TGF-beta-induced SpB gene repres-
sion that involves interactions between specific
SMAD3 domains and the corresponding functional
sites on NKX2.1 and FOXA1 transcription factors.
INTRODUCTION
Transforming growth factors-beta (TGF-beta) are a
large family of secreted polypeptides with established
roles in nearly every aspect of cellular physiology,
pathology and tumorigenesis. In the lung, as in other
organs, TGF-beta regulates tissue morphogenesis and
cellular diﬀerentiation through regulation of target
gene expression (1). Although regulation of gene expres-
sion by TGF-beta is complex, from a simplistic perspec-
tive, the binding of TGF-beta ligand to its receptors,
TbRII and TbRI initiates a cascade of phosphorylation
events that eventually result in nuclear translocation of
SMAD2 and SMAD3 subsequent to their association with
SMAD4. To date, much has been elucidated regarding the
mechanisms of TGF-beta-induced gene activation.
However, TGF-beta also inhibits gene transcription and
comparatively much less is known about the latter
mechanism.
Surfactant protein-B, SPB is a protein constituent of
pulmonary surfactant, a surface-active material that
stabilizes lung alveoli and is therefore critical to air
breathing. As a key component of pulmonary surfactant,
SPB is absolutely required for postnatal survival.
In humans, inherited SPB deﬁciency is a lethal condition
that requires lung transplantation. Targeted inactivation
of SpB in mouse also causes perinatal lethality (2). Even
reduced SPB perturbs lung function in both humans and
transgenic mice (3,4). Increased bioactive TGF-beta is
associated with a number of pathological lung conditions,
including interstitial lung ﬁbrosis (5,6) and bronchopul-
monary dysplasia, BPD (7). TGF-beta was found to
inhibit the expression of SpB, but the precise mechanism
remained unknown (8).
Expression of SpB is dependent on the activity of
a number of transcription factors. The role of the
homeodomain transcription factor NKX2.1, (otherwise
known as TTF-1 or TEBP) is central, illustrated by the
observation that in Nkx2.1(–/–) embryonic lungs SpB gene
activity is entirely lacking (9). Many signaling cues during
lung development or in response to injury are mediated
through physical and functional interactions of NKX2.1
with other nuclear factors. These interactions modulate
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For example, NKX2.1 interacts with the nuclear
factors, TAZ (a transcriptional co-activator with
PDZ-binding domain) and NFI (nuclear Factor I) to
activate transcription from the lung-speciﬁc SpC gene
(10,11). TAZ interacts with the amino-terminal domain
of NKX2.1 increasing its transcription activation proper-
ties. The 50 ﬂanking region of the SpB gene also includes
binding sites for members of the forkhead/winged
helix transcription factors, FOXA1/FOXA2. In transient
transfection studies, the latter binding sites were found to
be critical for SpB promoter activity (12). Compound
genetic disruption of Foxa1/Foxa2 loci eliminates epithe-
lial cell diﬀerentiation and consequently results in
the absence of SpB mRNA (13).
Previously, we showed that TGF-beta repression of
SpB transcription in lung epithelial cells occurs through
TbRI signaling and mediated by SMAD3 (14). No
evidence for direct binding of SMAD3 to the SpB
promoter was found, and a DNA-binding mutant of
SMAD3 eﬀectively repressed SpB, eliminating direct
DNA-binding requirement. Mutations within a 70bp
domain of SpB promoter that includes binding sites
for NKX2.1 and FOXA proteins eliminated SMAD3-
dependent repression of transcription. Further studies
suggested interactions between SMAD3 and both
NKX2.1 and FOXA1 proteins. We therefore proposed
that SMAD3 interactions with NKX2.1 and FOXA1
underlie the molecular basis for TGF-beta-induced
repression of SpB transcription. In the present study,
we have elucidated the precise nature and the sites of
interaction between SMAD3 and the two transcription
factors NKX2.1 and FOXA1 using a number of experi-
mental approaches. The sum of the results show that
interaction of SMAD3 occurs through the MH1 and MH2
domains of SMAD3 and lead to inhibition of NKX2.1
and FOXA1 binding to their cognate sites within the
SpB promoter.
MATERIALS AND METHODS
Plasmid construction
Complete coding region of rat Foxa1, rat Foxa2
and human Nkx2.1 were PCR ampliﬁed from cDNA
clones (a gift from Dr Costa, University of Illinois at
Chicago) veriﬁed by sequencing and cloned into EcoRI
and BamHI sites (for Foxa1 and Foxa2) or EcoRI
and HindIII sites (for Nkx2.1), in translational frame
with VP16 coding region of pVp16 vector (Clontech, CA,
USA), and designated Vp16-Foxa1, Vp16-Foxa2 and
Vp16-Nkx2.1 respectively. Vp16-Foxa1N, Vp16-Foxa1DB
and Vp16-Foxa1C were constructed by cloning the
speciﬁc Foxa1 fragments that encodes amino acids
1–137, amino acids 138–317 and amino acids 318–466,
into EcoRI and BamHI sites of pVp16. Similar strategy
was used for making GAL4 fusion constructs containing
speciﬁc domain fragments of Nkx2.1. Gal4-Nkx2.1N,
Gal4-Nkx2.1HD and Gal4-Nkx2.1C were constructed
by cloning the speciﬁc Nkx2.1 fragments that encodes
amino acids 1–141, amino acids 142–253 and amino
acids 254–371, into EcoRI and BamHI, BamHI and MluI,
MluI and HindIII sites of pM (Clontech, CA, USA),
respectively.
Gal4-Smad3, Vp16-Smad3 and glutathione-
S-transferase, GST-Smad3 were provided by Dr R.
Derynck (UCSF, CA, USA). Construction of Gal4-MH1,
Gal4-MH2 and Gal4-LNKR have been described (15).
Cell cultureand transient transfection assays
The human pulmonary epithelial cell lines A549 and H441
were maintained in F-12K Nutrient Mixture (Amersham
Biosciences, NJ, USA) containing 10% fetal bovine serum
and 1% penicillin–streptomycin. All plasmids used in
transfection studies were puriﬁed on QIAGEN columns
(Qiagen, CA, USA). Transient transfection of A549 cells
was performed with SuperFect as described by the
manufacturer (Qiagen, CA). After transfection, cells
were lyzed and the extracts were collected as described
(Promega, WI, USA). Supernatants of the cell extracts
were used for assay of b-galactosidase and luciferase as
described by the manufacturer (Promega, WI). MLE15
cells were cultured as described (16) and used for
extracting nuclear protein for EMSA.
Mammalian two-hybrid assay
Expression constructs for GAL4-fusion protein (1.125mg)
and VP16-fusion protein (5.625mg) were cotransfected
with the GAL4-luciferase reporter constructs Gal4-Lux
(3.375mg, pFR-Luc, Stratagene) and pSV-b-gal (Promega,
WI) into A549 cells. The interaction between GAL4-
fusion proteins and VP16-fusion protein as indicated in
each experiment was measured as a function of transacti-
vation of the heterologous GAL4 promoter as quantiﬁed
by luciferase production. Vectors including pM and pVp16
(Clontech, CA), were used in transfection experiments
as control for GAL4-fusion protein and VP16-fusion
protein.
Oligonucleotides
Synthetic oligonucleotides were annealed and diluted
as described (12) and used directly in EMSA as cold
competitor. For use as probe in EMSA reactions, the
annealed oligonucleotides were puriﬁed by gel electro-
phoresis on 3% low melting agarose (Promega, WI),
excised and then eluted using QIAEXII (Qiagen, CA).
Two picomoles of the puriﬁed, annealed oligonucleotides
were end-labeled with T4 polynucleotide kinase and
g-
33P-ATP as described (14). The labeled probes were
puriﬁed from unincorporated g-
33P-ATP using G-25
Sephadex column (Roche Applied Science, IN, USA).
The DNA sequence of the oligonucleotides are as follows.
For NKX2.1 binding: 50-CAC CTG GAG GGC TCT
TCA GAG C-30 (12). For FOXA1 binding: 50-CAA AGA
CAA ACA CTG AGG TCG-30 (12).
Electrophoretic mobility shiftassay(EMSA)
Nuclear extracts were prepared from MLE15 cells using
a mini-extraction procedure (12). Five micrograms of
the nuclear extract were incubated with
33P-end-labeled
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in 12.5mM Tris–HCl (pH 7.5), 62.5mM NaCl, 0.62mM
DTT, 10% glycerol, 0.05% NP-40, 0.05mg/ml Poly(dI-dC)
in a total volume of 20mla t4 8C for 15min.
For experiments with antibody or GST fusion proteins,
4ml antibody or 4.8mg GST fusion protein were mixed
with the nuclear extracts in reaction mixture
and incubated at 48C for 15min before addition of
the
33P-end-labeled probe. Bound and free probes
were separated by gel electrophoresis on a 4.5%
non-denaturing polyacrylamide gel. The NKX2.1
antibody was purchased from Lab Vision Corporation
(CA, USA). The FOXA1 antibody was purchased from
(CeMines, Co, USA).
Glutathione-S-transferase (GST) fusion proteinpurification
Cultures of Escherichia coli were transformed with
plasmids expressing either GST or GST-SMAD3 fusion
proteins. Recombinant proteins were isolated by ultra-
sonication, followed by puriﬁcation using Bulk GST
puriﬁcation module as described by the manufacturer
(Amersham Biosciences, NJ, USA).
Co-immunoprecipitation and western blotting
Co-immunoprecipitation was performed as previously
described (14). Brieﬂy, proteins were extracted from
H441 cells transfected with expression of the appropriate
construct and incubated with antibody against NKX2.1,
FOXA1 or FLAG (SMAD3-fusion). The Protein G
beads (Roche Applied Science, IN, USA) were washed
and added to the reaction mixture. After incubation
for 1h at 48C on a rotator, the beads were washed
thoroughly and resuspended in 2  reducing loading
buﬀer (Active Motif, CA, USA) for western blot analysis.
As negative control, a parallel reaction was performed
without the inclusion of the antibody. Antibodies used
for immunoprecipitation were mouse anti-FLAG (Sigma,
MI), mouse anti-NKX2.1 (Lab Vision Corporation, CA,
USA), and mouse anti-FOXA1 (Seven Hills Bioreagents,
OH, USA) antibodies. Western blots were performed with
either rabbit anti-NKX2.1 (Seven Hills Bioreagents, OH),
rabbit anti-FOXA1 (CE Mines, CO, USA), or rabbit
anti-SMAD3 (Abcam, MA, USA) antibodies.
Chromatin immunoprecipitation assay (ChIP)
ChIP assays were performed using a ChIP-IT
TM kit
(Active Motif, Inc., Carlsbad, CA, USA) following
the manufacturer0s instructions. Unless otherwise stated,
all reagents, buﬀers and supplies were included in the
kit. Brieﬂy, MLE15 cells were cross-linked with 1%
formaldehyde for 10min at room temperature. After
washing and treatment with glycine Stop-Fix solution,
the cells were resuspended in lysis buﬀer and incubated
for 30min on ice. The cells were homogenized and nuclei
were resuspended in shearing buﬀer and subjected
to optimize enzymatic shearing conditions to yield
100–400bp DNA fragments. The chromatin was
pre-cleared with protein G beads and incubated
(overnight at 48C) with 3mg of negative control mouse
IgG (provided in the ChIP-IT
TM kit) and anti-NKX2.1
polyclonal antibody (Seven Hills Bioreagents, Cincinnati,
OH). Protein G beads were then added to the antibody/
chromatin incubation mixtures and incubated for 1.5h at
48C. After extensive washings, the immunoprecipitated
DNA was removed from the beads in an elution buﬀer.
To reverse cross-links and remove RNA, 5M NaCl and
RNase were added to the samples and incubated for 4h at
658C. The samples were then treated with proteinase K for
2h at 428C, and the DNA was puriﬁed using DNA
puriﬁcation mini-columns. The puriﬁed DNA was sub-
jected to PCR ampliﬁcation (1 cycle of 948C for 3min,
35 cycles of 948C for 20s, 588C for 30s and 728C for 30s).
For assessment of NKX2.1 occupancy of the SpB
promoter, the primers used in PCR were: ATT TGA
CGG TGA ACA AAG TCA GGC T (forward for
NKX2.1 and FOXA1-binding sites); GAC CTC AGT
GTT TGC CTG TGT CT (reverse for NKX2.1); and TCT
TAT AGT AGG GGA GAG GAC CTG (reverse for
FOXA1) (17).
RESULTS
SMAD3interacts with FOXA1& NKX2.1
inamammalian two-hybrid assay
A mammalian two-hybrid assay in the lung carcinoma,
A549 cell line was used to determine physical interactions
between SMAD3 and NKX2.1 or FOXA1. Accordingly,
a construct expressing GAL4-fused-SMAD3 was transi-
ently cotransfected with another construct that expresses a
VP16-fused-NKX2.1 protein and the interactions were
monitored by luciferase production from a Gal4-luciferase
reporter construct (Figure 1, Panel A). In a separate set
of experiments, we used VP16-fused-FOXA1 to determine
its interactions with SMAD3 (Figure 1, Panel B). In both
sets of studies SMAD3 interacted physically with either
NKX2.1 or FOXA1 to bring about stimulation of the
Gal4-luciferase reporter construct. FOXA1 and FOXA2
are nearly 93% identical in their primary structure (18).
Using a VP16-FOXA2 fusion protein in a mammalian
two-hybrid assay showed that FOXA2 also interacts
with SMAD3 in a similar manner as FOXA1 (Figure 1,
Panel B). The above results clearly indicated physical
and robust interactions between FOXA1, NKX2.1 and
the TGF-beta-activated SMAD3.
To verify the two-hybrid assay data, we further
examined the impact of interactions of bacterially
expressed and puriﬁed glutathione-S-transferase, GST-
fused-SMAD3 on the binding of NKX2.1 and FOXA1 to
their cognate-binding sites by EMSA. Using MLE15
nuclear extracts, we examined the binding of nuclear
proteins to a 22bp oligonucleotide representing the
cognate-binding site for NKX2.1 (Materials and
Methods section). This analysis showed the formation of
at least four nucleoprotein complexes (Figure 2, Panel A,
Lane 1). Incubation of the nuclear extract with an
unlabeled oligonucleotide that has identical DNA
sequence to that of the probe competed eﬀectively for
the formation of the four complexes (Figure 2, Panel A,
Lane 2), whereas inclusion of a monoclonal anti-NKX2.1
antibody in the reaction mixture supershifted a complex
Nucleic Acids Research,2008, Vol. 36,No. 1 181as designated by the arrow (Lane 3). Inclusion of a
bacterially expressed and puriﬁed GST-fused-SMAD3
protein competed, in a dose-dependent manner for the
formation of all four complexes, but particularly the larger
complexes (lanes 5–7). Importantly in the control
reaction, 3.5mg of GST protein alone had no impact on
the formation of any of the four complexes (Lane 4).
These results clearly show that GST-SMAD3 protein
interferes, in a dose-dependent manner, with the binding
of NKX2.1 to its target sequences under in vitro
settings (Figure 2).
Similar analyses for FOXA1 using an oligonucleotide
representing the cognate FOXA1-binding site on the SpB
promoter identiﬁed multiple nucleoprotein complexes
(Figure 2, Panel B, Lane 1). The formation of the majority
of these complexes was inhibited upon inclusion of an
unlabeled oligonucleotide (Lane 2). Inclusion of a poly-
clonal anti-FOXA1 antibody resulted in the formation of
a supershifted complex (Lane 3, Arrow). As in Figure 2,
Panel A, a recombinant GST protein alone did not
compete for the formation of any of the complexes,
whereas inclusion of a recombinant GST-SMAD3 fusion
protein signiﬁcantly reduced the formation of the com-
plexes (Lanes 4 and 5, respectively). Dose-dependent
inhibition was not conducted for GST-SMAD3 with
FOXA1. These data demonstrate that interaction between
SMAD3 and FOXA1 reduce the binding of the latter
transcription factor to its cognate-binding site in vitro.
SMAD3 interacts withspecific domains
of NKX2.1 and FOXA1
To identify the speciﬁc domains on the NKX2.1 molecule
that mediate the NKX2.1–SMAD3 interactions, we
constructed Gal4-fusion plasmids containing one of
the three functional domains on the NKX2.1 protein;
the NH2-terminus, the homeodomain and the COOH-
terminus (Figure 3, Panel A). Each of the latter domains
is thought to render distinct roles in transcriptional
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Figure 1. SMAD3 interacts with NKX2.1 (Panel A) and both FOXA1
and FOXA2 (Panel B) in lung epithelial cells. Mammalian two-hybrid
assays were performed in A549 cells using Vp16-Nkx2.1, Vp16-Foxa1
or Vp16-Foxa2 expression plasmids according to the protocol described
in Materials and Methods section. Luciferase readings from the
controls consisting of, empty Vp16 and Gal4 plasmids alone, or in
combination with Vp16-Nkx2.1, Vp16-Foxa1 or Vp16-Foxa2 were
adjusted to unity and used to normalize all experimental results.
Representative results from three independent experiments are shown.
Asterisks denote P<0.05.
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Figure 2. EMSA analysis of SMAD3 interactions with NKX2.1 (Panel A) and FOXA1 (Panel B). A representative EMSA showing the results of an
experiment with nuclear extracts from MLE15 cells to analyze nucleoproteins bound to an oligonucleotide of the binding sites for NKX2.1 or
FOXA1 within the SpB promoter. Please note supershifted complex with either NKX2.1 or FOXA1 antibodies in Lane 3, Panel A and Lane 3 Panel
B, respectively (arrows). In panel A, increasing amounts of GST-SMAD3 were used to examine the eﬀect on the binding aﬃnity of NKX2.1.
182 Nucleic Acids Research, 2008, Vol. 36, No. 1activation function of NKX2.1. The use of the mamma-
lian two-hybrid assay in A549 cells showed little, if any
physical interactions between SMAD3 and the DNA
binding, homeodomain region of NKX2.1 (Figure 3,
Panel B). In contrast, as evidenced by the level of
luciferase production, both the NH2- and the COOH-
terminal ends of NKX2.1 interacted strongly with
SMAD3 indicating the two regions ﬂanking the NKX2.1
homeodomain to be the sites of interaction involved
in inhibition of DNA-binding function.
Similarly, we determined the functional domains of
FOXA1 molecule that are the sites of physical interactions
with SMAD3 (Figure 4, Panel A). In order to eliminate
spurious artifacts stemming from speciﬁc fusion con-
structs, we generated the SMAD3 constructs as GAL4,
rather than VP16-fusion proteins. The results with the
full-length FOXA1 (Vp16-Foxa1) were identical, whether
Vp16-Smad3 or Gal4-Smad3 fusion constructs were used,
thereby validating the results of the mammalian two-
hybrid assay. Figure 4, Panel B also shows evidence
for physical interaction between SMAD3 and the winged
helix DNA-binding domain of FOXA1. In addition,
there was measurable interaction between SMAD3 and
the transactivation domain of FOXA1 localized to
the NH2 terminus. However, this interaction only
approached, but did not reach statistical signiﬁcance
(P=0.071). SMAD3 interaction with the latter two
functional domains of FOXA1 was weak when compared
to the full-length protein, suggesting that overlapping
domains may be required for optimized interactions
(Figure 4).
SMAD3domains involvedin NKX2.1
andFOXA1 interactions
Three speciﬁc functional domains, which cover the
entire SMAD3 molecule were generated as Gal4-fusion
constructs. These are the domains in the NH2-terminus
(amino acids 1–130), also known as the MH1 domain,
the linker domain represented by amino acids 130–230
(LNKR) and the COOH-terminus or MH2 domain
(amino acids 230–424). These constructs were then used
in a mammalian A549 cell two-hybrid assay with either
GAL4-fused-NKX2.1 (Figure 5, Panel A) or GAL4-fused-
FOXA1 expression constructs (Figure 6 Panel A).
The results showed signiﬁcant interactions between full-
length NKX2.1 and the MH1 domain of SMAD3
(Figure 5). The interaction between NKX2.1 and the
SMAD3 MH2 domain did not reach statistical signiﬁ-
cance (P=0.083). Little if any interaction was
observed with the SMAD3 LNKR domain (P=0.25).
Furthermore, EMSA with GST-fused domains of
SMAD3 veriﬁed the two-hybrid assay ﬁndings (Figure 5,
Panel B). Consistent with the two-hybrid results, robust
interaction was found between NKX2.1 and the SMAD3
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Figure 3. Physical interactions between SMAD3 and functional
domains of NKX2.1. GAL4 or VP16 fused NKX2.1 and its various
functional domains were used in mammalian two-hybrid assays to
determine the site of interactions with SMAD3. Vp16 or Gal4 plasmids
were used either alone or in combination with other expression vectors
as control. Luciferase reading from combination of empty Vp16 and
Gal4 plasmids were adjusted to unity and used for normalization of all
experimental values. Representative results from three independent
experiments are shown. Asterisks denote P<0.05.
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Figure 4. Physical interactions between SMAD3 and functional
domains of FOXA1. GAL4 or VP16 fused FOXA1 and its functional
domains were used in mammalian two-hybrid assays to determine the
site of interactions with SMAD3. Empty Vp16 or Gal4 plasmids were
used either alone or in combination with other expression plasmids as
controls. Luciferase reading from combination of empty Vp16 and Gal4
plasmids were adjusted to unity and used for normalization of all
experimental values. Representative results from three independent
experiments are shown. Asterisks denote P<0.05.
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MH2 domain was also documented. However, no inter-
action was observed between LNKR domain of SMAD3
and NKX2.1 (Figure 5, Panel B, Lane 8). In contrast to
the interactions with NKX2.1, signiﬁcant interaction with
FOXA1 occurred mainly with the SMAD3 MH2 domain
(Figure 6). The two-hybrid assay showed only weak
interactions between FOXA1 and either SMAD3 MH1
or LNKR peptides. However, GST-fused-MH1 competed
eﬀectively against FOXA1 binding to its target DNA,
either indicating the inherent diﬀerences between the two
techniques or suggesting more complex interactions
between the two proteins (Figure 6, Panel B).
Co-immunoprecipitation of FOXA1, SMAD3 and NKX2.1
To further examine the interactions amongst
NKX2.1, FOXA1 and SMAD3 proteins, we used
co-immunoprecipation (co-IP). A Smad3-Flag expression
construct was transfected into H441 cells, which exhibit
endogenous Foxa1 and Nkx2.1 gene expression, and the
cellular extracts were used for co-IP with mouse anti-
FLAG, anti-NKX2.1 and anti-FOXA1 antibodies. We
used three antibodies to minimize the possibility of false-
negative results stemming from their intrinsic properties
that may interfere with protein–protein interactions in
co-IP studies. The immunoprecipitated complexes were
resolved by gel electrophoresis and western blot analysis
using rabbit-derived antibodies to the three proteins. The
results are summarized in the table in Figure 7. Anti-
FLAG, as expected, immunoprecipitated SMAD3 but
also FOXA1, indicating measurable physical interactions
by this antibody between SMAD3 and FOXA1, but not
NKX2.1. Anti-NKX2.1 immunoprecipitated a complex
that included only NKX2.1 and FOXA1, but not
SMAD3. Finally, only FOXA1 was brought down by
anti-FOXA1 antibodies, even though SMAD3–FOXA1
and NKX2.1–FOXA1 intracellular associations were
established by anti-FLAG and anti-NKX2.1 co-IP
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Figure 5. Localization of SMAD3 functional domains, which interact
with NKX2.1. Panel A, mammalian two-hybrid assays were used to test
the ability of GAL4-fused MH1, GAL4-fused MH2 or GAL4-fused
LNKR domains of SMAD3 to interact with a full-length VP16-fused
NKX2.1. Empty Gal4 plasmid was used as control and the results were
adjusted to unity. All experimental values were normalized against the
latter (Materials and Methods section). Panel B, representative EMSA
analysis of interactions between various domains of SMAD3 with
NKX2.1 on the SpB promoter. Supershifted nucleoprotein complex
with anti-NKX2.1 antibody is indicated with an arrow (Lane 3). Please
note that inclusion of GST-LNKR in EMSA does not interfere with
formation of nucleoprotein complexes (Lane 8). Asterisks denote
P<0.05.
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Figure 6. Localization of SMAD3 functional domains, which interact
with FOXA1. Panel A, mammalian two-hybrid assay was used to test
the ability of GAL4-fused MH1, GAL4-fused MH2 or GAL4-ﬁsed
LNKR domains of SMAD3 to interact with a full-length VP16-fused
FOXA1 protein. Results with the empty Gal4 plasmid were adjusted to
unity and used to normalize all experimental values (Materials and
Methods section). Panel B, representative EMSA analysis of interac-
tions between various domains of SMAD3 with FOXA1 on the SpB
promoter. Supershifted nucleoprotein complex with anti-FOXA1 anti-
body is indicated with an arrow (Lane 3, and a longer exposure in
Lane 9). Please note that only GST-LNKR does not interfere with
formation of nucleoprotein complexes (Lane 8). Asterisks denote
P<0.05.
184 Nucleic Acids Research, 2008, Vol. 36, No. 1results (Figure 7). Therefore, failure of anti-FOXA1 to
co-immunoprecipitate NKX2.1 or SMAD3, a false-
negative result, may be explained by an intrinsic
property of this antibody (e.g. its epitope speciﬁcity may
interfere with protein–protein interactions). Similarly,
it is possible that absence of demonstrable NKX2.1–
SMAD3 interactions by co-IP may simply be related
to speciﬁc aspects of the antibodies used.
TGF-betatreatment ofMLE15 cellsreduces the bindingof
NKX2.1 and FOXA1 to their targetgenomic sites invivo
To examine the in vivo relevance of the studies described
above, we performed chromatin immunoprecipitation
studies (ChIPs) using nuclear extracts from MLE15 cells.
Chromatin fractions were prepared from MLE15
cells treated with and without 10ng/ml of human
recombinant TGF-beta and immunoprecipitated using
an anti-NKX2.1 monoclonal antibody and a polyclonal
anti-FOXA1 antibody. Subsequent to isolation of DNA
from the immunoprecipitate, speciﬁc oligonucleotide
primers were used to PCR amplify a region of the SpB
promoter located between –222 and –74nt, for the
NKX2.1 reaction and –222 and –24nt, for the FOXA1
reaction. This region includes the binding sites for both
NKX2.1 and FOXA1. The experiments were repeated
three times with identical results. For NKX2.1 reaction
(Figure 8, Panel A), comparison between the intensities
of the PCR bands obtained in chromatin prepared
from TGF-beta-treated (Figure 8, Panel A, Lane 6)
versus untreated (Lane 5) samples supports the concept
that TGF-beta treatment diminishes the binding of
NKX2.1 to its target sequences in vivo. Similarly,
comparison between PCR products in Lanes 5 and 6
(Figure 8, Panel B) clearly shows that treatment of
MLE15 cells with TGF-beta ligand diminishes the binding
of FOXA1 to its target sequences on the SpB promoter
in vivo.
DISCUSSION
The purpose of the current study was to elucidate the
mechanisms of TGF-beta-induced, SMAD3-mediated
SpB gene repression. We found robust interactions
between SMAD3 and two lung-enriched transcription
factors, NKX2.1 and FOXA1, both of which are known
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Figure 7. Co-immunoprecipitation of FOXA1, SMAD3 and NKX2.1.
Co-immunoprecipitation with three antibodies, anti-FOXA1, anti-
NKX2.1 and anti-FLAG (against Smad3) was performed from extracts
of lung carcinoma cells transfected with a Smad3-Flag expression
construct. The co-IP complexes were analyzed by western blotting using
rabbit-derived antibodies to the three target proteins. C=Control
(no co-IP antibody), FO=anti-FOXA1 antibody, N=anti-NKX2.1
antibody and FL=anti-FLAG (SMAD3) antibody. The table is a
summary of the ﬁndings.
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Figure 8. Chromatinimmunoprecipitation(ChIP)analysisofSpBpromoteroccupancyforNKX2.1(PanelA)andFOXA1(PanelB)inresponsetoTGF-
beta in MLE15 cells. TGF-beta-treated MLE15 nuclear extracts were immunoprecipitated with either anti-NKX2.1 or anti-FOXA1 antibodies and
speciﬁc regions of the SpB promoter (Please see Materials and Methods section) were analyzed by PCR. Arrows indicate the PCR products. Lanes 1 are
molecular weight markers. Representative results from two independent experiments are shown.
Nucleic Acids Research,2008, Vol. 36,No. 1 185positive regulators of SpB gene expression (12). The sites
of interactions with SMAD3 were identiﬁed as the
NH2- and COOH-terminal domains of NKX2.1 and
principally the winged helix DNA-binding domain of
FOXA1. SMAD3 interacted with these proteins through
its MAD homology domains MH1 and MH2. Although
interactions between SMADs and homeodomain proteins
of Drosophila and Xenopus have been reported (19),
NKX2.1 is the ﬁrst mammalian member of this family
whose interactions with SMAD3 result in repression of
gene expression.
SMADs are intracellular eﬀectors of TGF-beta
signaling (1,20). In the lung, TGF-beta/SMAD signal-
ing ﬁgures importantly in normal development as well as
disease (5,7,21). In addition to activating batteries of genes
(e.g. ﬁbronectin, collagen), TGF-beta also represses a
number of genes including SpB (19). Although TGF-beta
signaling is mediated through both Smad2 and Smad3,
to date, in the handful of reported studies in which TGF-
beta acts as an inhibitor, Smad3 has been identiﬁed as
the key mediating mechanism (19). Consistent with these
studies, we found SMAD3 to mediate TGF-beta-induced
SpB gene repression in lung epithelial cell lines (14).
SMAD3 is composed of two conserved functional
domains, the NH2-terminal MH1 and the COOH-terminal
MH2 domains, separated by a non-conserved linker
domain (LNKR). In the current study, the two-hybrid
assays in Figures 5 and 6 identiﬁed both MH1 and MH2
domains of SMAD3 as sites of interaction with NKX2.1
and FOXA1, respectively. These results were further
veriﬁed by the EMSA studies shown in the same
Figures (Panels B). Consistent with the two-hybrid assay
results, only GST-fused SMAD3, MH1 and MH2
domains and not LNKR inhibited FOXA1 and NKX2.1
DNA binding. The MH1 domain is involved in DNA
binding and nuclear translocation but also negatively
regulates the functions of the MH2 domain (22,23).
The MH2 domain is critical for homo- and hetero-
oligomerization of SMADs, as well as the recognition and
phosphorylation by type I receptors (1,20). Interactions
between transcription factors and SMAD3 through
the MH2 or MH1 domains have been reported (19). By
far the majority of the reported cases lead to cooperativity
and positive regulation of gene expression by TGF-beta.
In the few cases in which TGF-beta, through SMAD3
represses gene expression, the sites of interaction were
localized to either MH1 or MH2 domains (19).
We also determined the speciﬁc domains of NKX2.1
and FOXA1 with which SMAD3 interacts. The sites of
interaction with SMAD3 were found to be localized to the
NH2- and COOH-terminal domains of NKX2.1. Little to
no interaction was observed with the NKX2.1 HD
domain. Both NH2- and COOH-terminal domains of
NKX2.1 have been found to aﬀect transactivation
function of NKX2.1 in target gene transcription (24).
The results of the mammalian two-hybrid assays
(Figure 4) are consistent with the latter ﬁndings. These
domains alone were able to render transactivation
function to the GAL4 DNA-binding domain and activate
transcription from the GAL4-responsive reporter with
VP16 (Figure 3). The HD of NKX2.1 had no
transactivation function. Despite these observations,
interactions of SMAD3 with NKX2.1 resulted in an
overall reduction of DNA-binding aﬃnity, as assessed by
EMSA in Figure 2. Thus, TGF-beta-induced, SMAD3-
mediated repression of SpB may aﬀect not only DNA
binding, but also transactivation function of NKX2.1.
FOXA1and FOXA2 proteins share 93% amino acid
homology in the winged helix DNA-binding domain
and bind to the same DNA consensus sequences (18).
The winged helix DNA-binding domain is the site of
protein–DNA interactions and may also contain the
nuclear localization signal (25). The FOXA proteins also
include conserved NH2- and COOH-terminal transcrip-
tional activation domains that are involved in protein–
protein interactions (26). Regions II and III sequences
within the COOH-terminal domain are essential in
transcriptional activation (25,27). In the current study,
the DNA binding, winged helix domain of FOXA1
was found to be the principal site of interaction with
SMAD3. No statistically signiﬁcant interaction was
measurable between SMAD3 and either the COOH- or
NH2-terminal domains of FOXA1. Interaction with
SMAD3 reduced the DNA-binding aﬃnity of FOXA1
for its target sequences on the SpB promoter. Interactions
between other forkhead/winged helix family members,
FOXH1 and FOXO with both SMAD2 and SMAD3
have also been documented, although the sites of
interaction remain unknown (28,29).
To examine the in vivo relevance of our ﬁndings, we
used two approaches. First, using antibodies to each of the
three proteins, we showed that complexes consisting of
NKX2.1, FOXA1 and SMAD3 can be co-immunopreci-
pitated (Figure 7). However, the antibodies failed
to demonstrate direct NKX2.1–SMAD3 interactions by
co-IP. We propose that this may be due to speciﬁc intrinsic
properties of the antibodies used. An alternative conclu-
sion is that physical interactions between SMAD3 and
NKX2.1 occur only through FOXA1. This possibility
however is unlikely in the face of the internally consistent
data from the stringent analyses conducted in multiple
two-hybrid and EMSA assays with full length and
fragments of all three proteins (Figures 1, 3 and 5).
These latter studies ﬁrmly established direct and
robust physical interactions between the COOH- and
NH2-domains of NKX2.1 and SMAD3.
In a second approach, ChIP analysis showed that TGF-
beta decreased promoter occupancy on the SpB gene
for both NKX2.1 and FOXA1, suggesting that TGF-beta
signaling, through SMAD3 destabilizes the binding of
NKX2.1 and FOXA1 to their target DNA sites. A number
of mechanisms may be invoked to explain the latter
ﬁndings. The possibility that SMAD3 may bind and
displace NKX2.1 or FOXA1 (competitive inhibition) does
not appear likely for two reasons: First, EMSA analysis
has failed to identify SMAD3 as a component of
nucleoprotein complexes found on the SpB promoter
(data not shown). Second, and consistent with the latter,
a SMAD3 mutant lacking the DNA-binding domain is
equally competent in inhibiting SpB transcription as
the wild-type protein (14). Therefore, we favor a model
in which interactions between SMAD3 and either
186 Nucleic Acids Research, 2008, Vol. 36, No. 1NKX2.1 or FOXA1 occurs independently of the DNA
thereby preventing the binding of the latter transcription
factors to their target site (Figure 9). Although examples
of TGF-beta-induced, SMAD3-mediated gene repression
are few, a number of ﬁndings are consistent with
the results of our study in this report. For example,
TGF-beta-inhibition of myogenic diﬀerentiation is
mediated by SMAD3 interaction with MyoD and
myogenin. SMAD3 interacts directly with the HLH
domains of MyoD or myogenin and interferes with
heterodimerization of the latter with their obligatory
partner E12/47, thus decreasing their binding to their
DNA target site (30).
TGF-beta signaling is crucial during normal lung
development and maintenance of homeostasis in postnatal
life. In addition, many injuries to the lung are character-
ized by dysregulated TGF-beta signaling. The impact of
TGF-beta is manifested in a variety of ways that range
from interstitial ﬁbrosis to interruption of alveolar
development. Although the overall pathway of TGF-
beta signaling may appear simple, physical and functional
interactions between its components, such as SMAD3
and other key transcriptional regulators, such as NKX2.1
provide the means for a profound degree of signaling
speciﬁcity and versatility. Undoubtedly, characterization
of the interactions between SMAD3 and NKX2.1 or
FOXA1 will aid our understanding of the speciﬁcity
with which TGF-beta signaling functions in various
physiological contexts and therefore its impact on both
normal and pathological processes.
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